导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.94% | 3298/4773 |
| 近一周 | -1.31% | 2002/5465 |
| 近一月 | -1.23% | 1070/5421 |
| 近一季 | -0.54% | 1083/5231 |
| 近半年 | -1.61% | 1831/4920 |
| 近一年 | -0.97% | 2918/4394 |
| 近两年 | 32.41% | 2192/2954 |
| 近三年 | 19.57% | 1503/2253 |
| 成立以来 | 47.47% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.40% 4124/4961 |
6.16% 2846/5312 |
- - |
- - |
| 2025 | 14.14% 2618/4813 |
-0.71% 2369/3635 |
2.52% 1514/4076 |
10.21% 3312/4524 |
1.73% 1242/4813 |
| 2024 | 17.17% 720/3463 |
3.23% 609/2808 |
-0.26% 722/3014 |
15.90% 1597/3129 |
-1.80% 1837/3463 |
| 2023 | -9.09% 1104/2656 |
0.74% 1705/2280 |
-4.64% 1234/2385 |
1.42% 311/2515 |
-6.70% 1880/2655 |
| 2022 | -16.30% 471/2207 |
-10.87% 442/1919 |
6.40% 710/2016 |
-12.68% 761/2113 |
1.07% 1396/2208 |
| 2021 | -6.55% 1012/1822 |
-2.22% 599/1255 |
0.44% 1100/1330 |
-6.66% 976/1466 |
1.94% 743/1822 |
| 2020 | 26.88% 592/1250 |
-9.68% 708/1028 |
11.30% 738/1067 |
12.83% 360/1164 |
11.87% 514/1184 |
| 2019 | 26.35% 576/1092 |
12.65% 706/739 |
3.85% 43/788 |
1.85% 350/850 |
6.05% 659/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 建信上证50ETF发起联接C VS. 长安沪深300非周期A(740101) |